Once daily treatment with Denali's oral candidate DNL343 failed to reduce NfL levels in adults with ALS in the HEALEY trial.

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its target price reduced by Bank of America from $30.00 to $28.00 in ...

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) were down 8.9% during trading on Monday after Bank of America lowered their price target on the stock from $30.00 to $28.00. Bank of ...

BofA lowered the firm’s price target on Denali Therapeutics (DNLI) to $28 from $30 and keeps a Buy rating on the shares. The firm updated for ...

Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the ...

Denali Therapeutics Inc.’s DNLI share price has dipped by 10.43%, which has investors questioning if this is right time to buy.

We recently compiled a list of the Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In. In this article, we ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) today. The company’s ...

Nevertheless, the new disappointment with DNL343 is another major disappointment to ALS patients, who have limited drug ...

Denali Therapeutics DNLI reported a fourth-quarter 2024 loss of 67 cents per share, narrower than the Zacks Consensus ...

Oppenheimer analyst Jay Olson lowered the firm’s price target on Denali Therapeutics (DNLI) to $42 from $50 and keeps an Outperform rating on the shares following quarterly results and after hosting ...

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31 ...